
Arabinosylcytosine, Cytarabine

Printed from https://www.cancerquest.org/patients/drug-reference/arabinosylcytosine-cytarabine on 04/18/2024




Brand name: Cytosar® Brand name: ara-C IUPAC: 4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one FDA approval: Yes <u>Manufacturer Link</u> Usage:

Malignancies for which cytarabine is used include: Acute non-lymphocytic leukemia, Acute lymphocytic leukemia and Chronic myelocytic leukemia. Cytarabine (Cytosar®, ara-C) is administered as an infusion or as in injection under the skin.

Mechanism:

Cytarabine (Cytosar®, ara-C) is an antimetabolite that acts as a pyrimidine antagonist. It is thought that its primary activity is interrupting DNA synthesis.



The molecular structure above shows Arabinosylcytosine, Cytarabine.

Side effects:

Common side effects include: bone marrow suppression, anorexia, nausea and vomiting, diarrhea, oral/analinflammation or ulceration, rash, fever. Cytarabine (Cytosar®, ara-C) is a suppressor of bone marrow activity. It is important to monitor blood cell and platelet counts throughout the duration of treatment with blood tests done often. $\underline{1}$

• <u>1</u>Cytosar. Product Monograph. Pfizer. September, 2014. [http://www.pfizer.ca/sites/g/files/g10017036/f/201410/cytosarnon-annotated-pm-175940-E.pdf]

Contraindications:

Cytarabine should not be taken by women who are pregnant and patients should not become pregnant while using this drug, as it may have harmful affects on the developing fetus. 1

 <u>1</u>Cytosar. Product Monograph. Pfizer. September, 2014. [http://www.pfizer.ca/sites/g/files/g10017036/f/201410/cytosarnon-annotated-pm-175940-E.pdf]